Skip to main content
. 2019 Jan 1;9(1):180–185.

Figure 3.

Figure 3

RNase 5 attenuates cetuximab-mediated suppression on colon cancer cell growth and migration. A. HT29 cells were treated with cetuximab (50 μg/ml) in the presence or absence of RNase 5 protein (0.5 μg/ml) and subjected to MTT assay. B. HT29 cells were subjected to cell migration assay in the presence or absence of cetuximab (C225) and RNase 5.